There are 412 resources available
198P - Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009
Presenter: Antonio LLOMBART CUSSAC
Session: Lunch and Poster Display session
199P - Adoptive PD1+ tumor-infiltrating lymphocyte therapy for metastatic TNBC: First results of the safety run-in phase of the TILS001 clinical trial
Presenter: Laura Angelats
Session: Lunch and Poster Display session
200P - Testing a higher dose (90 mg s.c.) of eftilagimod alpha, a soluble LAG-3 protein in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003
Presenter: Serafin Morales Murillo
Session: Lunch and Poster Display session
201P - The implementation of first-line pertuzumab and the impact on overall survival in patients with de novo HER2+ metastatic breast cancer in the Netherlands in 2008-2017: A population-based cohort study
Presenter: Nan Ding
Session: Lunch and Poster Display session
202P - Complete response rates, treatment patterns and survival outcomes in patients treated with first-line pertuzumab-based therapy in HER2-positive advanced breast cancer: A SONABRE study
Presenter: Nan Ding
Session: Lunch and Poster Display session
203P - Real-world treatment patterns in patients with HER2+ unresectable (u) or metastatic (m) breast cancer (BC): HER2 real study final analysis in Asia-Pacific (APAC) and Brazil
Presenter: Carlos Barrios
Session: Lunch and Poster Display session
204P - Clinical features predictive of never-progressive disease to first-line anti-HER2 therapy: Real-world data from the ESME national cohort
Presenter: Thomas Grinda
Session: Lunch and Poster Display session
205P - Trastuzumab biosimilar (TB) in combination with pertuzumab (P) and chemotherapy (ct) in HER2 positive, metastatic breast cancer (mBC): Efficacy and safety
Presenter: Gilles Freyer
Session: Lunch and Poster Display session
206P - Prognostic role of tumor-infiltrating lymphocytes (TILs) in first-line HER2-positive (HER2+) metastatic breast cancer (BC): A real-world study
Presenter: Beatrice Taurelli Salimbeni
Session: Lunch and Poster Display session
207P - Sequential therapy with HER2 tyrosine kinase inhibitors in patients with HER2-positive metastatic breast cancer
Presenter: Elena Shagisultanova
Session: Lunch and Poster Display session